propranolol + pyridostigmine

A combination therapy primarily used for the treatment of **Postural Tachycardia Syndrome (POTS)**, a form of dysautonomia. * **Propranolol:** A non-selective beta-adrenergic antagonist that reduces heart rate and blood pressure by blocking beta receptors. * **Pyridostigmine:** A cholinesterase inhibitor (e.g., brand name Mestinon) that increases acetylcholine levels at neuromuscular junctions, enhancing neuromuscular transmission. Clinical trials have investigated this combination for POTS, demonstrating significant improvement in orthostatic intolerance symptoms, depression, and quality of life. Typical research dosing has involved propranolol (10-20 mg twice daily) combined with pyridostigmine (30 mg twice daily). While effective, studies suggest the addition of pyridostigmine to propranolol may not provide significant *additional* benefits compared to propranolol alone for POTS symptoms. No direct drug-drug interactions were noted in the search results, but both medications have independent side effect profiles.